SPL801- RAPID ACTING ANTIDEPRESSANT

SPL801-速效抗抑郁药

• 批准号: 132669
• 金额: $ 17.79万
• 依托单位: SMALL PHARMA LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132669
• 关键词: SPL801; RAPID; ACTING; ANTIDEPRESSANT

This project is to conduct preclinical research into a promising new rapid-acting antidepressant. The standard of care in treating depression are selective serotonin reuptake inhibitors (SSRIs). A major drawback of SSRIs is that they are rarely effective in reducing suicidal ideation and suicidal behaviour during early treatment, particularly in young patients. Suicide is the leading cause of death in 20-34 year olds in the UK, and over 6000 suicides are registered in the UK each year. As many as 75% of suicide cases are associated with depression. This project builds on academic research which identifies a rapid-acting antidepressant which shows promise as a therapy to reduce suicidality in major depression patients. Very little is known about the physical form of the drug, or its suitability to pharmaceutical formulation. The outcome of this project is to understand the technical avenues available to prepare suitable dosage forms to investigate this drug in humans, paving the way for clinical trials.

本项目是对一种有前途的新型速效抗抑郁药进行临床前研究。治疗抑郁症的标准治疗是选择性5-羟色胺再摄取抑制剂（SSRIs）。SSRIs的一个主要缺点是，它们在早期治疗中很少有效地减少自杀意念和自杀行为，特别是在年轻患者中。自杀是英国20-34奥尔兹的主要死亡原因，每年有超过6000人自杀。多达75%的自杀病例与抑郁症有关。该项目建立在学术研究的基础上，该研究确定了一种速效抗抑郁药，该药物有望作为减少重度抑郁症患者自杀倾向的治疗方法。对药物的物理形式或其对药物制剂的适用性知之甚少。该项目的成果是了解可用于制备合适剂型的技术途径，以研究该药物在人体中的作用，为临床试验铺平道路。